Trial
NCT04639843
Doxorubicin, CC-(486) (5-azacitidine), Romidepsin, and Duvelisib (hARD) for T-cell Lymphoma
Phase IWITHDRAWNSAFETYConfidence: MEDIUM
Sponsor
National Cancer Institute (NCI)
Collaborators
—
Condition
Adult T-cell Leukemia/Lymphoma
Intervention
CC-486 (5-azacitidine)
Why stopped
Safety issues with PI3 kinase inhibitors
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2022-11-04